Moreover, the level of phosphorylated PDH-E1α was increased in the CML + β-GP group compared to that in the control group, suggesting that CML treatment increases PDK4 expression (Figure 4F; Supplementary Figure 3). This evidence concerns the gene PDK4 and chronic myelogenous leukemia, BCR-ABL1 positive.